These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31077601)

  • 21. A Decade of Improvement in Door-to-Needle Time Among Acute Ischemic Stroke Patients, 2008 to 2017.
    Tong X; Wiltz JL; George MG; Odom EC; Coleman King SM; Chang T; Yin X; ; Merritt RK
    Circ Cardiovasc Qual Outcomes; 2018 Dec; 11(12):e004981. PubMed ID: 30557047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
    Chen G; Wang X; Robinson TG; Pikkemaat M; Lindley RI; Zhou S; Ping L; Liu W; Liu L; Chalmers J; Anderson CS;
    J Neurol Sci; 2018 Apr; 387():1-5. PubMed ID: 29571842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
    Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D;
    N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.
    Chao AC; Han K; Lin SF; Lin RT; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Wei CY; Lin YT; Lee JT; Hu HH; Bai CH;
    J Neurol Sci; 2019 Apr; 399():76-81. PubMed ID: 30780072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke.
    Zhang B; Sun XJ; Ju CH
    Eur Neurol; 2011; 65(3):170-4. PubMed ID: 21372577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemorrhagic conversion after alteplase administration in a patient with vasculitis and acute ischemic stroke.
    Gilbert BW; Dhakal L; Lacy A; Huffman JB
    Am J Health Syst Pharm; 2019 Feb; 76(4):211-213. PubMed ID: 30689698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
    Cappellari M; Moretto G; Micheletti N; Donato F; Tomelleri G; Gulli G; Carletti M; Squintani GM; Zanoni T; Ottaviani S; Romito S; Tommasi G; Musso AM; Deotto L; Gambina G; Zimatore DS; Bovi P
    J Thromb Thrombolysis; 2014 May; 37(4):549-56. PubMed ID: 23943338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review.
    Qureshi AI; Malik AA; Freese M; Thompson MJ; Khan AA; Suri MF
    Am J Emerg Med; 2015 Feb; 33(2):307.e1-4. PubMed ID: 25190550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm.
    Chen X; Delcourt C; Sun L; Zhou Z; Yoshimura S; You S; Malavera A; Torii-Yoshimura T; Carcel C; Arima H; Hackett ML; Robinson T; Song L; Wang X; Lindley RI; Chalmers J; Anderson CS;
    Cerebrovasc Dis; 2020; 49(4):427-436. PubMed ID: 32702699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke.
    Liu J; Shi Q; Sun Y; He J; Yang B; Zhang C; Guo R
    J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):1126-1132. PubMed ID: 30655038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial.
    Minhas JS; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Donnan GA; Kim JS; Lavados PM; Lee TH; Martins SCO; Olavarría VV; Pandian JD; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Thang NH; Wang JG; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Cerebrovasc Dis; 2018; 45(5-6):213-220. PubMed ID: 29705803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review.
    Sarmiento RJC; Diestro JDB; Espiritu AI; San Jose MCZ
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104290. PubMed ID: 31371140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study.
    Teivane A; Jurjāns K; Vētra J; Grigorjeva J; Kupcs K; Masiliūnas R; Miglāne E
    Medicina (Kaunas); 2022 Aug; 58(9):. PubMed ID: 36143846
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
    Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS
    Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
    Wang X; Robinson TG; Lee TH; Li Q; Arima H; Bath PM; Billot L; Broderick J; Demchuk AM; Donnan G; Kim JS; Lavados P; Lindley RI; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sharma VK; Thang NH; Wang JG; Woodward M; Anderson CS; Chalmers J;
    JAMA Neurol; 2017 Nov; 74(11):1328-1335. PubMed ID: 28973174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
    Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
    Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.